Search

Your selection

Clear all

Filter by category

Filter by content type

Filter by content year

News

Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

January 15, 2026 - … Media and Investor Relations :  FINN Partners IR@vaxart.com Source: Vaxart, Inc. Vaccine was safe and well-tolerated … Media and Investor Relations :  FINN Partners IR@vaxart.com Source: Vaxart, Inc. Vaccine was safe and well-tolerated … Media and Investor Relations :  FINN Partners IR@vaxart.com Source: Vaxart, Inc. …
News

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

September 10, 2025 - … from norovirus by providing better immunity at the site of virus entry. With second-generation constructs that … Relations:  Matt Steinberg FINN Partners IR@vaxart.com (646) 871-8481 A photo accompanying this announcement is … from norovirus by providing better immunity at the site of virus entry. With second-generation constructs that …
News

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

May 27, 2025 - … Relations          Matt Steinberg FINN Partners IR@vaxart.com (646) 871-8481 This press release was published by a … Relations          Matt Steinberg FINN Partners IR@vaxart.com (646) 871-8481 This press release was published by a … Relations          Matt Steinberg FINN Partners IR@vaxart.com (646) 871-8481 This press release was published by a …
News

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults

March 5, 2025 - … in generating mucosal antibody responses beyond the site of administration SOUTH SAN FRANCISCO, Calif. , March … Relations : Matt Steinberg FINN Partners IR@vaxart.com (646) 871-8481 Source: Vaxart, Inc. Robust, … in generating mucosal antibody responses beyond the site of administration SOUTH SAN FRANCISCO, Calif. , March …
News

Vaxart Provides Business Update

June 17, 2024 - … is critical as it generates an immune response at the site of the infection and may also provide better protection … Mark Herr FINN Partners Vaxart, Inc.   mherr@vaxart.com IR@vaxart.com (203) 517-8957   Source: Vaxart, Inc. — Cash runway … is critical as it generates an immune response at the site of the infection and may also provide better protection …
News

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

April 30, 2024 - … Relations: Mark Herr Vaxart, Inc. mherr@vaxart.com (203) 517-8957 Investor Relations: Andrew Blazier FINN Partners IR@vaxart.com (646) 871-8486 Source: Vaxart, Inc. Antibody rise … Relations: Mark Herr Vaxart, Inc. mherr@vaxart.com (203) 517-8957 Investor Relations: Andrew Blazier FINN …
News

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

December 21, 2023 - … Mark Herr      Vaxart , Inc.      mherr@vaxart.com (203) 517-8957 Investor Relations:        Andrew Blazier FINN Partners IR@vaxart.com (646) 871-8486  Source: Vaxart, Inc. On track to report … Mark Herr      Vaxart , Inc.      mherr@vaxart.com (203) 517-8957 Investor Relations:        Andrew Blazier …
News

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

November 2, 2023 - … Blazier Vaxart , Inc.      FINN Partners mherr@vaxart.com IR@vaxart.com (203) 517-8957       (646) 871-8486    Source: Vaxart, … Blazier Vaxart , Inc.      FINN Partners mherr@vaxart.com IR@vaxart.com (203) 517-8957       (646) 871-8486    Source: Vaxart, … Blazier Vaxart , Inc.      FINN Partners mherr@vaxart.com IR@vaxart.com (203) 517-8957       (646) 871-8486    …
News

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

July 6, 2023 - … optimized for delivery to the gastrointestinal system, the site at which norovirus enters the body. Today’s results add …     Mark Herr      Vaxart , Inc.      mherr@vaxart.com (203) 517-8957       Investor Relations:         Andrew Blazier FINN Partners IR@vaxart.com (646) 871-8486   Source: Vaxart, Inc. Met all primary …
News

Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate

February 14, 2023 - … Vaxart Media Relations: Mark Herr Vaxart, Inc mherr@vaxart.com (203) 517-8957 Investor Relations: Andrew Blazier FINN Partners IR@vaxart.com (646) 871-8486 Source: Vaxart, Inc. Study to evaluate … Vaxart Media Relations: Mark Herr Vaxart, Inc mherr@vaxart.com (203) 517-8957 Investor Relations: Andrew Blazier FINN …
Scroll to Top